![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to focus on the clinical development of TRK-820 (nalfurafine hydrochloride), which is being evaluated for the treatment of Uremic Pruritus.
Lead Product(s): Nalfurafine
Therapeutic Area: Dermatology Product Name: TRK-820
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Toray Industries Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 22, 2024
Details:
IMMUNA (IMM01-STEM) is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules, which is investigated for the treatment of Muscle Atrophy.
Lead Product(s): IMM01-STEM
Therapeutic Area: Musculoskeletal Product Name: IMMUNA
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
IMM01-STEM, a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules, in participants with muscle atrophy related to knee osteoarthritis (KOA).
Lead Product(s): IMM01-STEM
Therapeutic Area: Musculoskeletal Product Name: IMM01-STEM
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023